3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Status
Unknown
1
Recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
9
Tumor-Agnostic
6
Gastrointestinal
4
Head & Neck
3
Gynecologic
3
Thoracic
2
Lymphoid
2
Genitourinary
2
Dermatologic
2
Sarcoma
1
Plasma cell
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
7
Breast Neoplasms
6
Lung Neoplasms
5
Ovarian Neoplasms
4
Colorectal Neoplasms
4
Pancreatic Neoplasms
3
Urinary Bladder Neoplasms
2
Prostatic Neoplasms
2
Neoplasms
2
Inflammation
2
Colonic Neoplasms
2
Carcinoma, Hepatocellular
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Thrombosis
1
Thromboembolism
1
Stomach Neoplasms
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Rectal Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Lymphoma
1
KRAS Mutant Non-Small Cell Lung Cancer
1
Immune System Diseases
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Interventions
pembrolizumab
61
Carboplatin
44
Pemetrexed
31
Paclitaxel
31
Docetaxel
31
Cisplatin
27
Gemcitabine
24
Nivolumab
23
Erlotinib Hydrochloride
21
Bevacizumab
18
Ipilimumab
11
osimertinib
10
Drug Therapy
10
atezolizumab
9
Radiosurgery
9
Cyclophosphamide
9
Cetuximab
9
Blood Specimen Collection
9
durvalumab
8
cemiplimab
8
Radiotherapy
8
budigalimab
7
Fluorouracil
7
Dexamethasone
7
trametinib
6
fludarabine
6
dostarlimab
6
avelumab
6
Taxes
6
130-nm albumin-bound paclitaxel
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms
×
palbociclib
×
Thoracic
×
Clear all
NCT06307249
2024-03-12
PTST_PALBEVA
Lebanese University
Phase 1
Recruiting
50 enrolled
NCT06065592
2023-10-06
CAT_PB
Lebanese University
Phase 1
Unknown
500 enrolled